Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-000269
Filing Date
2023-01-13
Accepted
2023-01-13 16:31:39
Documents
35
Period of Report
2022-11-30

Document Format Files

Seq Description Document Type Size
1 10-Q bzyr-20221130x10q.htm   iXBRL 10-Q 690510
2 EX-31.1 bzyr-20221130xex31d1.htm EX-31.1 11666
3 EX-31.2 bzyr-20221130xex31d2.htm EX-31.2 11950
4 EX-32.1 bzyr-20221130xex32d1.htm EX-32.1 6693
5 EX-32.2 bzyr-20221130xex32d2.htm EX-32.2 7123
  Complete submission text file 0001558370-23-000269.txt   2184718

Data Files

Seq Description Document Type Size
6 EX-101.SCH bzyr-20221130.xsd EX-101.SCH 18922
7 EX-101.CAL bzyr-20221130_cal.xml EX-101.CAL 17150
8 EX-101.DEF bzyr-20221130_def.xml EX-101.DEF 51261
9 EX-101.LAB bzyr-20221130_lab.xml EX-101.LAB 155839
10 EX-101.PRE bzyr-20221130_pre.xml EX-101.PRE 98804
29 EXTRACTED XBRL INSTANCE DOCUMENT bzyr-20221130x10q_htm.xml XML 222644
Mailing Address 9432 KATY FREEWAY HOUSTON TX 77055
Business Address 12000 RICHMOND AVE HOUSTON TX 77082 (713) 335-5697
BURZYNSKI RESEARCH INSTITUTE INC (Filer) CIK: 0000724445 (see all company filings)

EIN.: 760136810 | State of Incorp.: DE | Fiscal Year End: 0228
Type: 10-Q | Act: 34 | File No.: 000-23425 | Film No.: 23529125
SIC: 2835 In Vitro & In Vivo Diagnostic Substances